Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Subcutaneous Ascending Doses of MWN105 Injection in Healthy Chinese Volunteers
NCT07801313 is registered in ClinicalTrials.gov with Shanghai Minwei Biotechnology Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Subcutaneous Ascending Doses of MWN105 Injection in Healthy Chinese Volunteers
- Lead sponsor
- Shanghai Minwei Biotechnology Co., Ltd
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 19, 2024
- Completion date
- July 20, 2025
- Enrollment
- 55 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
mash - metabolic dysfunction-associated steatohepatitis, overweight , obesity, type 2 diabetes mellitus (t2dm)